Bio Investments Group (BIG) and International Vaccine Institute (IVI) Forge Partnership to Accelerate Vaccine Self-Reliance in Africa and the Middle East
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International Vaccine Institute (IVI), an international organization dedicated to advancing vaccine discovery, development, and delivery, today announced the signing of a Memorandum of Understanding (MoU) to establish a...
Australian Dentists Endorse Smartee’s Mandibular Repositioning Technology at Global Symposium in Kunming
Clinicians praise the S8-SGTB appliance for accelerating outcomes, improving patient satisfaction, and offering a non-invasive solution for Class II malocclusions. KUNMING, China, July 11, 2025 /PRNewswire/ -- Smartee Denti-Technology recently welcomed orthodontic experts and partners from Australia at its Global Symposium in Kunming, China. The event offered a deep dive into Smartee's Mandibular Repositioning Technology and showcased its...
Angel Yeast Unveils 2024 Sustainability Report, Showcasing Commitment to Green Practices and Innovation
SHANGHAI, July 11, 2025 /PRNewswire/ -- Angel Yeast (600298.SH) recently released its 2024 Sustainability (ESG) Report, providing in-depth insights into the company's thoughts and actions towards sustainable development management. The report highlights significant efforts across key areas, including social responsibility, sustainable procurement, talent development, innovation, green practices, and corporate governance. It also marks...
QNET Unveils Wellness Breakthroughs and Global Empowerment at V-Malaysia 2025
Over 8,000 global entrepreneurs gather in Penang for five days of wellness innovation and mentorship. HONG KONG, July 11, 2025 /PRNewswire/ -- QNET kicked off V-Malaysia 2025, its flagship global convention, uniting more than 8,000 entrepreneurs from over 30 countries for five days of immersive learning, innovation, and mentorship. The V-Malaysia 2025 stage comes...
Dräger Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Respiratory Devices Innovation
Dräger recognized for pioneering innovations in respiratory care, delivering measurable improvements in patient outcomes, clinical efficiency, cost-effectiveness and critical care training SAN ANTONIO, July 10, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Dräger has received the 2025 Global Company of the Year Award in the respiratory devices industry for its outstanding achievements in clinical innovation,...
LG Debuts Next-Generation Precision Medical AI
Joint Development Underway: World-Class Precision Medical AI Platform with Vanderbilt University Medical Center SEOUL, South Korea, July 10, 2025 /PRNewswire/ -- LG AI Research announced on July 9 the official launch of 'EXAONE Path 2.0', its next-generation precision medical AI model. Following the introduction of its 1.0 model in August of last year, LG AI Research showcased its 1.5 model last month...
Lifecykel Launches Ground Breaking Mongolian Training Program with UFC Legends Jorge Masvidal and Batgerel Danaa
ULAANBAATAR, Mongolia, July 10, 2025 /PRNewswire/ -- UFC legend Jorge Masvidal, famously known as the "King of Miami," and Mongolian MMA icon Batgerel Danaa are teaming up for a new chapter in elite human performance. The two fighters are working alongside Lifecykel to lead a high-performance training initiative in Mongolia, united by a shared philosophy: the destruction of...
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HXN-1001 in healthy volunteers. HXN-1001 is a half-life extended next-generation anti-TL1A antibody...
Tokyo Lifestyle Co., Ltd. Reports Fiscal Year 2025 Financial Results
TOKYO, July 10, 2025 /PRNewswire/ -- Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand and the United Kingdom, today announced its financial results for...
Vita Therapeutics and I Peace announced a development program to generate iPS-derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS...
PALO ALTO, Calif., July 10, 2025 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy. GMP-grade iPS cells...
